ARTELO BIOSCIENCES, INC. Proceeds from Notes Payable
ARTELO BIOSCIENCES, INC. (ARTL) reported Proceeds from Notes Payable of $29.40 thousand for the 12-month period ending 2017-08-31, per its 10-K filed 2018-11-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2018-11-29
- ARTELO BIOSCIENCES, INC. proceeds from notes payable for the quarter ending 2017-08-31 was $0.00.
- ARTELO BIOSCIENCES, INC. proceeds from notes payable for the quarter ending 2017-05-31 was $0.00.
- ARTELO BIOSCIENCES, INC. proceeds from notes payable for fiscal 2017 was $29.40K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2017-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $0.00 derived: sum of 2 quarters · filed 2018-11-29 | $29.40K 10-K · filed 2018-11-29 | |
| 2017-05-31 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-07-13 | $29.40K 10-Q · filed 2018-07-13 | ||
| 2017-02-28 | $29.40K 10-Q/A · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |